Jorge A Marrero

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 36:1349-54. 2002
  2. ncbi request reprint Staging systems for hepatocellular carcinoma: should we all use the BCLC system?
    Jorge A Marrero
    J Hepatol 44:630-2. 2006
  3. doi request reprint The challenge of prognosis and staging for hepatocellular carcinoma
    Jorge A Marrero
    Multidisciplinary Liver Tumor Program, University of Michigan, Ann Arbor, Michigan 48109, USA
    Oncologist 15:23-33. 2010
  4. doi request reprint Modern diagnosis and management of hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Clin Liver Dis 13:233-47. 2009
  5. pmc Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
    Jorge A Marrero
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 137:110-8. 2009
  6. ncbi request reprint Hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA
    Clin Liver Dis 10:339-51, ix. 2006
  7. ncbi request reprint Hepatocellular carcinoma
    Jorge A Marrero
    University of Michigan, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 22:248-53. 2006
  8. ncbi request reprint GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:1007-12. 2005
  9. ncbi request reprint Screening tests for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Clin Liver Dis 9:235-51, vi. 2005
  10. ncbi request reprint Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 41:707-16. 2005

Research Grants

Collaborators

Detail Information

Publications48

  1. ncbi request reprint NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 36:1349-54. 2002
    ..Because of the increasing incidence of NAFLD, further studies are needed to determine the risk of HCC in patients with NAFLD...
  2. ncbi request reprint Staging systems for hepatocellular carcinoma: should we all use the BCLC system?
    Jorge A Marrero
    J Hepatol 44:630-2. 2006
  3. doi request reprint The challenge of prognosis and staging for hepatocellular carcinoma
    Jorge A Marrero
    Multidisciplinary Liver Tumor Program, University of Michigan, Ann Arbor, Michigan 48109, USA
    Oncologist 15:23-33. 2010
    ..Although more work is required, it is hoped that these and other ongoing research efforts will eventually enable the development of a global staging classification...
  4. doi request reprint Modern diagnosis and management of hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    Clin Liver Dis 13:233-47. 2009
    ..Resection, transplantation, and percutaneous ablation are considered curative interventions and are currently applied to about 30% of all patients with HCC...
  5. pmc Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
    Jorge A Marrero
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Gastroenterology 137:110-8. 2009
    ..The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels...
  6. ncbi request reprint Hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA
    Clin Liver Dis 10:339-51, ix. 2006
    ..Resection, transplantation, and percutaneous ablation are considered curative interventions and are applied to about 30% of all patients who have HCC. Currently, there is no standard therapy for advanced HCC...
  7. ncbi request reprint Hepatocellular carcinoma
    Jorge A Marrero
    University of Michigan, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 22:248-53. 2006
    ..Our aim is to review the latest information regarding the risk factors, markers for early detection, diagnosis, and therapy for this tumor type...
  8. ncbi request reprint GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:1007-12. 2005
    ..Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC...
  9. ncbi request reprint Screening tests for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Clin Liver Dis 9:235-51, vi. 2005
    ..The latter point is the main limitation of surveillance for HCC. In this review we will discuss the currently available tests for the surveillance of HCC...
  10. ncbi request reprint Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 41:707-16. 2005
    ..The BCLC staging system includes aspects of all of these elements and provided the best prognostic stratification for our cohort of patients with HCC...
  11. ncbi request reprint Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass
    Jorge A Marrero
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 11:281-9. 2005
    ..If additional studies confirm our results, the noninvasive criteria utilized to make a diagnosis of HCC should be revised...
  12. ncbi request reprint Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor 48109, USA
    Hepatology 37:1114-21. 2003
    ..810, respectively (P =.002). In conclusion, DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease. Prospective studies to evaluate the role of DCP in early HCC are underway...
  13. ncbi request reprint Newer markers for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 127:S113-9. 2004
    ..There is an urgent need for novel biomarkers for the detection of early HCC; the National Cancer Institute proposal provides a framework for future validation studies...
  14. ncbi request reprint Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3
    Michael L Volk
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Cancer Biomark 3:79-87. 2007
    ..In conclusion, DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Serum biomarkers may be less sensitive and specific in the highest risk patients...
  15. doi request reprint Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma
    Amit G Singal
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    J Clin Gastroenterol 45:727-32. 2011
    ..Patient factors associated with surveillance rates are incompletely understood...
  16. doi request reprint Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis
    Amit G Singal
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Cancer Epidemiol Biomarkers Prev 21:793-9. 2012
    ..Surveillance for hepatocellular carcinoma (HCC) is recommended in patients with cirrhosis, but the effectiveness of a surveillance program in clinical practice has yet to be established...
  17. doi request reprint Renal outcomes after liver transplantation in the model for end-stage liver disease era
    Pratima Sharma
    Division of Gastroenterology, University of Michigan, Taubman Center, Ann Arbor, MI 48109, USA
    Liver Transpl 15:1142-8. 2009
    ..Further studies of modifiable preoperative, perioperative, and postoperative factors influencing renal function are needed to improve outcomes following LT...
  18. doi request reprint Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
    Amit G Singal
    Department of Internal Medicine, UT Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas 75390 8887, USA
    Am J Gastroenterol 108:425-32. 2013
    ....
  19. ncbi request reprint Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence
    Pratima Sharma
    University of Michigan Health Systems, Division of Gastroenterology and Department of Pathology, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:1100-8. 2007
    ..Similar to non-LT patients, those with lower pretreatment HCV RNA, a week 12 virological response, and pegylated IFN and RBV dose adherence were more likely to achieve SVR...
  20. doi request reprint An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data
    Shawn J Pelletier
    Division of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 15:859-68. 2009
    ..The current criteria for liver transplantation of candidates with HCC lead to acceptable 5-year survival while limiting the dropout rate. Liver Transpl 15:859-868, 2009. (c) 2009 AASLD...
  21. doi request reprint Portal vein thrombosis and survival in patients with cirrhosis
    Michael J Englesbe
    Division of Transplantation, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 16:83-90. 2010
    ..39; 95% CI, 2.39-22.83). In conclusion, patients with cirrhosis complicated by PVT have an increased risk of death...
  22. doi request reprint Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival
    Theodore H Welling
    Departments of Surgery and Medicine, Sections of Transplantation and Hepatology, University of Michigan Health System, MI 48109, USA
    Cancer Invest 30:689-97. 2012
    ..15; 95%CI:1.21-3.74) and stage (HR 1.92; 95%CI:1.22-3.97) independently predicted mortality; while viral etiology was protective (HR 0.69; 95%CI:0.41-0.98). Therefore, HCC IL-8 mediated events may be worthy of future investigation...
  23. ncbi request reprint Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
    Jorge A Marrero
    Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 42:218-24. 2005
    ..The role of tobacco as a risk factor for HCC is controversial. Recently, obesity has been reported to be a risk factor for HCC. We investigated whether these factors increase the risk of HCC in American patients...
  24. pmc Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study
    Mina O Rakoski
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 5362, USA
    Hepatology 55:184-91. 2012
    ..Individuals with cirrhosis received more than twice the number of informal caregiving hours per week (P < 0.001), at an annual cost of US $4700 per person...
  25. doi request reprint MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies
    Jonathon M Willatt
    Department of Radiology MRI, University of Michigan Health System, UH B2A209K, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0030, USA
    Radiology 247:311-30. 2008
    ..MR findings following ablation and chemoembolization are also reviewed...
  26. ncbi request reprint Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma
    Michael L Volk
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Transplantation 82:1136-9. 2006
    ....
  27. ncbi request reprint Modified Charlson comorbidity index for predicting survival after liver transplantation
    Michael L Volk
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Liver Transpl 13:1515-20. 2007
    ..We demonstrate the usefulness of a modified comorbidity index, the CCI-OLT, for predicting posttransplantation survival...
  28. doi request reprint Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver
    Asra S Khan
    Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Magn Reson Imaging 32:360-6. 2010
    ....
  29. doi request reprint Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
    Chanunta Hongthanakorn
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
    Hepatology 53:1854-63. 2011
    ..8 months after the VBT. Four patients had persistently undetectable HBV DNA, six had transient increase in HBV DNA during follow-up, and none had GR...
  30. pmc Failure rates in the hepatocellular carcinoma surveillance process
    Amit G Singal
    Division of Gastroenterology, Dedman Scholar of Clinical Care, University of Texas Southwestern, 5959 Harry Hines Blvd, POB 1, Suite 420, Dallas, TX 75390 8887, USA
    Cancer Prev Res (Phila) 5:1124-30. 2012
    ..Future interventions must target multiple failure points in the surveillance process to be highly effective...
  31. ncbi request reprint A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 38:518-26. 2003
    ..Application of this index may decrease the need for staging liver biopsy specimens among CHC patients...
  32. ncbi request reprint Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice
    Thomas M Shehab
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Clin Gastroenterol Hepatol 2:425-31. 2004
    ....
  33. ncbi request reprint Hepatocellular carcinoma
    Jorge A Marrero
    Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Curr Opin Gastroenterol 21:308-12. 2005
    ..Our aim is to review the latest information regarding the risk factors, surveillance and diagnosis of this tumor...
  34. ncbi request reprint Early detection of liver cancer: diagnosis and management
    Michael L Volk
    Division of Gastroenterology and Hepatology, University of Michigan Health System, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Curr Gastroenterol Rep 10:60-6. 2008
    ..A new oral agent, sorafenib, was recently shown to prolong survival in patients with advanced HCC. By increasing surveillance and treatment of HCC, outcomes for these patients may be improved...
  35. doi request reprint Role of liver transplantation in the treatment of cholangiocarcinoma
    Amit Singal
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109, USA
    Expert Rev Anticancer Ther 9:491-502. 2009
    ....
  36. ncbi request reprint Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique
    Katherine E Maturen
    Department of Radiology, University of Michigan Hospitals, Ann Arbor, MI 48019 0030, USA
    AJR Am J Roentgenol 187:1184-7. 2006
    ..Reported seeding rates range from 0.6% to 5.1% using various biopsy techniques. To our knowledge, the rate of seeding using a coaxial cutting needle technique has not been reported...
  37. ncbi request reprint Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature
    Ryan M Taylor
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 12:781-91. 2006
    ..Corticosteroids and immunoglobulin infusions were effective in 50% while the remainder of patients required rituximab infusions or eventual splenectomy for long-term disease remission...
  38. pmc Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists
    Pratima Sharma
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA
    Dig Dis Sci 56:569-77. 2011
    ..Our aim was to assess gastroenterologists' knowledge of HCC management guidelines established by the American Association for the Study of Liver Diseases (AASLD) and usual clinical practice...
  39. doi request reprint Recent advances in the treatment of hepatocellular carcinoma
    Amit G Singal
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Curr Opin Gastroenterol 26:189-95. 2010
    ..Surgical resection, liver transplantation, and local ablative therapies such as radio frequency ablation offer the chance of a cure for tumors detected at an early stage in well selected patients...
  40. ncbi request reprint Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109 0362, USA
    J Hepatol 43:937-43. 2005
    ..The aim of this study was to describe the clinical course of patients with adefovir-resistant HBV infection...
  41. doi request reprint Recent advances in the treatment of hepatocellular carcinoma
    Kunjali T Padhya
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas 75390 8887, USA
    Curr Opin Gastroenterol 29:285-92. 2013
    ..To provide an up-to-date summary of the recent advances in therapies for hepatocellular carcinoma (HCC)...
  42. doi request reprint Diagnosis and treatment of hepatocellular carcinoma
    Hashem B El-Serag
    Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas 77030, USA
    Gastroenterology 134:1752-63. 2008
    ..In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach...
  43. ncbi request reprint Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed?
    Michael Volk
    Gastroenterology 134:1612-4. 2008
  44. pmc Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis
    Anand S Mehta
    Drexel University College of Medicine and Department of Microbiology and Immunology and Drexel Institute for Biotechnology and Virology, Doylestown, PA 18901, USA
    J Virol 82:1259-70. 2008
    ..The reason for the alteration in the glycosylation of anti-Gal IgG is currently unclear but may be related to the natural history of the disease and may be useful in the noninvasive detection of fibrosis and cirrhosis...
  45. ncbi request reprint Viral hepatitis and hepatocellular carcinoma
    Carlos Romero Marrero
    University of Puerto Rico, San Juan, Puerto Rico
    Arch Med Res 38:612-20. 2007
    ..The diagnosis of HCC is established by the presence of an arterially enhancing mass in the presence of cirrhosis. Viral hepatitis represents an opportunity for prevention of HCC...
  46. ncbi request reprint Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?
    Jorge A Marrero
    Gastroenterology 126:347-50. 2004
  47. pmc Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements
    Heping Zhou
    The Van Andel Research Institute, 333 Bostwick, Grand Rapids, MI 49503, USA
    Genome Biol 5:R28. 2004
    ..Two-color RCA on antibody microarrays should allow the convenient acquisition of expression profiles from a great diversity of proteins for a variety of applications...
  48. ncbi request reprint SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma
    E Ellen Schwegler
    Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
    Hepatology 41:634-42. 2005
    ..In conclusion, SELDI-TOF MS serum profiling is able to distinguish HCC from liver disease before cirrhosis as well as cirrhosis, especially in patients with HCV infection compared with other etiologies...

Research Grants4

  1. Complications of Cirrhosis in American Patients
    Jorge Marrero; Fiscal Year: 2007
    ..I will supervise the conduct of the proposed research and meet with my mentors and advisors regularly. Completing this proposal will allow me to achieve my career goal and to contribute to an improve outcome of patients with HCC. ..
  2. Early Detection and Prognosis of Patients with Hepatocellular Carcinoma
    Jorge Marrero; Fiscal Year: 2007
    ..Therefore, identifying the risk factors, identifying new methods for early detection and determining prognosis for this tumor is of extreme importance. ..